Business
Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group
MALVERN, Pa., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it will present at the 2025 Annual Meeting of the Parkinson Study Group (PSG), taking place December 4-6, 2025 in San Diego, California. The presentation builds on momentum from the Company’s recent Ph
About this update from Annovis Bio, Inc.
[{"type":"image","alt":"Annovis Bio Inc.","displaySize":"","headline":null,"caption":"Annovis Bio Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":200,"height":200,"url":"https://media.zenfs.com/en/globenewswire.com/00e49d5ebf66ac512dbaabeac6cdd6eb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/plvHQ2cwqCYZbJvLkT5mUA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTM2MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/00e49d5ebf66ac512dbaabeac6cdd6eb","width":200,"height":200}},"lazy":false},{"type":"text","content":"MALVERN, Pa., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it will present at the 2025 Annual Meeting of the Parkinson Study Group (PSG), taking place December 4-6, 2025 in San Diego, California.","length":443,"tagName":"p"},{"type":"text","content":"The presentation builds on momentum from the Company’s recent Phase 3 PD biomarker data, showing that patients with amyloid co-pathology experience more pronounced cognitive decline, which is counteracted and reversed by buntanetap. In the same patients, buntanetap also reduces tau biomarkers, which are known to increase with disease severity.","length":345,"tagName":"p"},{"type":"text","content":"The presentation will also debut a cross-study comparison of the completed trials, providing the most comprehensive look yet at cognitive outcomes across all tested indications by Annovis and highlighting the population that benefits most – patients with amyloid pathology. In both Parkinson’s and Alzheimer’s, individuals with biomarker-confirmed presence of amyloid experience the greatest cognitive gain following buntanetap. These findings further validate the drug’s mechanism as a translational inhibitor of neurotoxic aggregating proteins and support the Company’s next strategic steps.","length":593,"tagName":"p"},{"type":"text","content":"Presentation details:","length":21,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Title: Amyloid co-pathology, cognitive decline, and improvement in buntanetap-treated Parkinson’s disease dementia patients","length":123,"tagName":"p"}]},{"val":[{"type":"text","content":"...